Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017
A look at financing, M&A and alliance activity April–June 2017
Executive Summary
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
You may also be interested in...
Spectranetics Gives Philips Adjacent Territory In Image-Guided Therapy
The plum in the middle of Philips' intense period of M&A this summer was the €1.9 billion purchase of Spectranetics, which, combined with Philips Volcano, should create a $1 billion+ devices business within the image-guided therapy group by 2020. IGT senior vice president and general manager Bert van Meurs explains the rationale behind the deal, and what's next for Philips.
Philips Puts Its Money On Electrical Geodesics – The Universal Brain Flashlight
The new-found interest in – and diagnostic and therapeutic potential of – EEG was described to In Vivo by Electrical Geodesics co-founder Ann Bunnenberg during the 2017 GMTCC in May. Not two months later, Philips had made the Oregon company another of its 2017 M&A conquests.
Philips Targets Bolt-On Deals That Meet Demand At The Point Of Care
Philips, a giant of the medical systems and software industry, maintains its strategic direction with organic and external growth. That was illustrated in one recent four-month period in which the group made seven acquisitions, adding to its non-invasive diagnostics portfolio Electrical Geodesics and bolstering its steps in therapeutic medical devices with the acquisition of Spectranetics. But whatever the target, the same ground rules apply.